Amgen Inc. is requesting U.S. regulatory approval under fast-track guidelines for palifermin, a first-in-class investigational compound for oral mucositis. (BioWorld Today)

Amgen Inc. is requesting U.S. regulatory approval under fast-track guidelines for palifermin, a first-in-class investigational compound for oral mucositis. (BioWorld Today)